These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32091262)

  • 1. Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.
    Miles J; Howell J; Sheridan D; Braucht G; Mericle A
    Am J Drug Alcohol Abuse; 2020 May; 46(3):266-272. PubMed ID: 32091262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deploying science to change hearts and minds: Responding to the opioid crisis.
    Walsh SL; Long KQX
    Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
    Sharma A; Kelly SM; Mitchell SG; Gryczynski J; O'Grady KE; Schwartz RP
    Curr Psychiatry Rep; 2017 Jun; 19(6):35. PubMed ID: 28526967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attitudes toward opioid use disorder medications: Results from a U.S. national study of individuals who resolved a substance use problem.
    Bergman BG; Ashford RD; Kelly JF
    Exp Clin Psychopharmacol; 2020 Aug; 28(4):449-461. PubMed ID: 31556675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 10. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.
    Klein AA; Seppala MD
    J Subst Abuse Treat; 2019 Sep; 104():51-63. PubMed ID: 31370985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. News Media Reporting On Medication Treatment For Opioid Use Disorder Amid The Opioid Epidemic.
    Kennedy-Hendricks A; Levin J; Stone E; McGinty EE; Gollust SE; Barry CL
    Health Aff (Millwood); 2019 Apr; 38(4):643-651. PubMed ID: 30933576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using buprenorphine to treat patients with opioid use disorder.
    Radi JK; Fogarty KJ; Lagerwey MD
    JAAPA; 2019 Oct; 32(10):30-35. PubMed ID: 31513035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Buprenorphine to Treat Opioid Use Disorder.
    Bartholow LAM; Pope J
    J Psychosoc Nurs Ment Health Serv; 2018 Nov; 56(11):9-12. PubMed ID: 30383881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responding to the opioid and overdose crisis with innovative services: The recovery community center office-based opioid treatment (RCC-OBOT) model.
    Ashford RD; Brown AM; McDaniel J; Neasbitt J; Sobora C; Riley R; Weinstein L; Laxton A; Kunzelman J; Kampman K; Curtis B
    Addict Behav; 2019 Nov; 98():106031. PubMed ID: 31326776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.
    Mackey K; Veazie S; Anderson J; Bourne D; Peterson K
    J Gen Intern Med; 2020 Dec; 35(Suppl 3):954-963. PubMed ID: 33145687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
    Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H
    Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
    Reif S; Brolin MF; Stewart MT; Fuchs TJ; Speaker E; Mazel SB
    J Subst Abuse Treat; 2020 Jan; 108():33-39. PubMed ID: 31358328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.